We aimed to investigate the efficacy and safety of the addition SBRT with CisGem in locally advanced inoperable CC.Methods:ABC-07 (ISRCTN:10639376) is a phase II multicentre randomized trial for patients with inoperable, histologically confirmed locally advanced CC, WHO performance status 0-1. ...
oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol. 2022;23(7):851-864.
Swaffer M, Brawner CA, Lanfear DE, Selektor Y, Velez M, Tita C, Keteyian SJ. Cardiac rehabilitation improves functional capacity and patient-reported health status in patients with continuous-flow left ventricular assist devices: the...
Los Angeles DA asks court to deny Menendez brothers' petition for new trial; Benjamin Bratt, Gretchen Mol talk love and marriage in their new movie Episode 37 Thu, Feb 20, 2025 Kaitlyn Conley manslaughter conviction overturned: Revisiting the poisoning case; Menendez brothers say ...
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemc... BACKGROUNDNew chemotherapeutic agents, including paclitaxel and gemcitabine, are active in advanced bladder carcinoma, and combination regimens with...
Effect of a Mediterranean-Style Diet on Endothelial Dysfunction and Markers of Vascular Inflammation in the Metabolic Syndrome: A Randomized Trial The metabolic syndrome consists of a constellation of factors that increase the risk of cardiovascular disease and type 2 diabetes. Recent estimates indica.....
标题:Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A for Nonrandomized, Open-label, Phase II Trial 作者:Xu, JM (Xu, Jianming); Shen, J (Shen, Jie); Gu, SZ (Gu, Shanzhi); Zhang, ...
[3]Xu BH, Yan M, Ma F, et al. PHOEBE Investigators. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomi...
Trial 1, because the magnitude of the electrical force exerted by Sphere Y on Sphere X was greater in Trial 1 than in Trial 7. B. Trial 1, because the magnitude of the electrical force exerted by Sphere Y on Sphere X was less in Trial 1 than in Trial 7. C. Trial 7, ...
Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose... and development factor (PEG-rHuMGDF ) is a potent stimulator of megakaryocytopoiesis and prevents chemotherapy-induced thrombocytopenia in preclinical...